Emergent BioSolutions Q1 net income surges 656% to $68M; revenue down 26% to $222.2M

Emergent BioSolutions Inc.

2025-Q1 EPS reported $1.19 revenue$222,200,000

Total revenues $222.2M, down 26% YoY; driven by 62% drop in NARCAN sales to $45.3M.
Net income $68.0M ($1.19 diluted EPS) vs $9.0M prior year; adjusted EBITDA $77.6M, up 16%.
MCM Products segment revenues $156.6M (+1%), driven by 112% increase in Smallpox MCM to $106.4M.
Board authorized $50M share repurchase through March 2026; reaffirmed FY 2025 revenue guidance $750-$850M.
Recent deals: $20M BioThrax contract option, $16.7M BARDA collaboration, exclusive U.S./Canada rights to KLOXXADO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.